Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026 Four oral presentations and three posters build upon Phase 3 ABTECT Maintenance and Induction programs in ulcerative colitis, long-term Phase 2 findings, and preclinical anti-fibrotic research PARIS, France –
Abivax Presents Business Updates and First Half 2026 Financial Results Chris Rabbat to succeed Fabio Cataldi as Chief Medical Officer; Tim Kelly appointed Chief Technical Officer to advance commercial supply readiness and lead Abivax’s Chemistry, Manufacturing and Controls (“CMC”), Quality and
Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative colitis by the end of 2026 PARIS, France – July 30, 2026 – 10:05 p.m.
Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments Appointed industry leaders bring decades of experience across commercial strategy, patient services, launch readiness, and field force development PARIS, France – July 23, 2026 – 10:05 p.m.